Trials / Recruiting
RecruitingNCT07400458
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
Detailed description
To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hearticellgram-AMI | Patients who had administered Hearticellgram-AMI. |
Timeline
- Start date
- 2022-03-03
- Primary completion
- 2028-10-12
- Completion
- 2032-09-30
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07400458. Inclusion in this directory is not an endorsement.